SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it has appointed Mark Erwin to the new position of vice president of commercialization. Mr. Erwin will be responsible for defining, developing and leading the company's commercial operations.
"We are pleased to have recruited Mark to our team," said Evan M. Levine, ADVENTRX chief executive officer. "Mark brings tremendous experience in commercialization and oncology product launch leadership, which will be crucial as we move forward with ANX-530, a novel emulsion formulation of vinorelbine, for which ADVENTRX plans to submit an NDA to the FDA next year, pending positive results from our on-going bioequivalence study."
Most recently, Mr. Erwin served as senior director of program development for Centric Health Finance, LLC, which offers financial services for private practice oncologists. Other prior roles include director of oncology marketing for Ligand Pharmaceuticals Corp. and head of government affairs and reimbursement for IDEC Pharmaceuticals, Inc. Mr. Erwin began his career in a variety of sales and marketing roles with Eli Lilly & Co., including product manager for the launch of Lilly's oncology business in the US, and he holds a degree in chemistry from Purdue University.
About ANX-530 (vinorelbine emulsion)
ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a
generic chemotherapy agent. ANX-530 is designed to reduce the incidence and
severity of vein irritation from IV-delivery of vinorelbine tartrate.
|SOURCE ADVENTRX Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved